AOD-9604 Peptide Research
AOD-9604 is a synthetic fragment of human growth hormone developed to explore lipolytic and anti-obesity effects without the full endocrine profile of native growth hormone.
metabolic peptide
Early Clinical
research maturity
Overview
AOD-9604 is a synthetic fragment of human growth hormone developed to explore lipolytic and anti-obesity effects without the full endocrine profile of native growth hormone. It remains investigational, and its online reputation often exceeds the strength of the published clinical evidence.
Comparisons
Related stacks
Metabolic Stack
Recomposition Stack
Mechanism
It is derived from the C-terminal region of hGH and is proposed to influence lipolysis and inhibit lipogenesis, with less impact on IGF-1 signaling than full-length growth hormone. That theoretical separation from classic GH effects is central to its appeal in body-composition medicine.
Clinical interest
Clinical interest focuses on obesity, body-fat reduction, and metabolic optimization, especially for people seeking a non-incretin approach or an adjunct to broader metabolic programs.
Research summary
Published human trials suggest AOD-9604 was generally tolerated and produced modest fat-loss signals in some settings, but development never reached the practice-changing level seen with semaglutide or tirzepatide. Reviews comparing GH fragments and obesity pharmacology reinforce that the efficacy signal appears modest rather than transformative.
Safety considerations
Human safety appears better characterized than many gray-market peptides, but long-term effectiveness remains uncertain and manufacturing quality is a separate issue outside formal pharmaceutical development. It should not be presented as an established obesity standard.
Key information
Research stage
Early Clinical
Evidence rating
Low
Search intent
informational
Last review
Mar 13, 2026
Featured studies
(
6
)
Frequently asked questions
What is AOD-9604?
AOD-9604 is a modified fragment of human growth hormone studied for fat-loss effects while attempting to avoid the broader anabolic and glycemic actions of full-length GH.
Does AOD-9604 work like semaglutide?
No. Semaglutide is an FDA-approved GLP-1 receptor agonist with large randomized outcome trials, जबकि AOD-9604 has a smaller and weaker evidence base centered on modest body-composition effects.